Online Only Articles

MLL partial tandem duplication leukemia cells are sensitive to small molecule DOT1L inhibition

Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA
Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA
Epizyme, Inc., Cambridge, MA, USA
Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA
Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA
Epizyme, Inc., Cambridge, MA, USA
The Comprehensive Cancer Center, The Ohio State University, Columbus, OH, USA
Divisions of Experimental Hematology and Cancer Biology, Cincinnati Children’s Hospital Medical Center, Cincinnati, OH, USA
Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA
Epizyme, Inc., Cambridge, MA, USA
Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA;Department of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, NY, USA
Vol. 100 No. 5 (2015): May, 2015 https://doi.org/10.3324/haematol.2014.115337